Shiv Rao built Abridge around the idea that clinical conversations, not isolated notes, power every downstream workflow in healthcare—from order entry to billing codes and patient education. A practicing cardiologist and former corporate investor, he launched the company in Pittsburgh in 2018 with CMU professor Zach Lipton. Today Abridge is live in more than 250 health systems, valued at about $5.3 billion, and aims to record over a million encounters per day this year. Under the hood, Abridge runs its own speech-to-text and clinical-insight models for roughly 70–80 percent of its workloads, swapping in large public models only where absolute perfection isn’t critical. Multiple in-house speech engines handle mispronounced drug names and new medication terms, while parallel “judge” and “QA” agents audit outputs. The team measures how fast they can swap frontier models into this orchestration, seeing it as a key agility metric. After raising around $800 million, Rao emphasizes that the founders still hold full control and aren’t chasing an IPO. He’s wary of strategic investors who sit on boards, insisting they stay minority shareholders to avoid conflicts. That governance stance, combined with Abridge’s focus on core enterprise-grade reliability over flashy one-off features, is Rao’s answer to “Why 126 AI scribes?”—platform depth beats weekend hacks.